Assess whether the primary endpoint will survive FDA scrutiny (aac33d)

SITUATION A company with a CMC site change mid-review has scientific-advice briefing book in hand following a pediatric ethicist objecting to the proposed design. Clinical-development physician must determine whether the primary endpoint will survive FDA scrutiny for this Pharma & Life Sciences FDA Response and Labeling file.

DECISION Clinical-development physician in a company with a CMC site change mid-review must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using scientific-advice briefing book after a pediatric ethicist objecting to the proposed design.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol on the primary endpoint will now if scientific-advice briefing book after a pediatric ethicist objecting to the proposed design already carries the FDA Response and Labeling discriminator for clinical-development physician. 2. Keep Pause the pathway in force until scientific-advice briefing book is completed after a pediatric ethicist objecting to the proposed design in a company with a CMC site change mid-review. 3. Treat scientific-advice briefing book as Escalate safety review because both Proceed under protocol and Pause the pathway appear after a pediatric ethicist objecting to the proposed design. 4. Clinical-development physician does not have the decision the primary endpoint will turns on in scientific-advice briefing book; refuse a Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a company with a CMC site change mid-review. 2. Trace CMC, labeling, or pharmacovigilance facts in scientific-advice briefing book after a pediatric ethicist objecting to the proposed design. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences FDA Response and Labeling file, read scientific-advice briefing book against a pediatric ethicist objecting to the proposed design and write the one fact that would move the primary endpoint will for clinical-development physician.

RECOMMENDATION On this Pharma & Life Sciences / FDA Response and Labeling decision, bind Proceed under protocol to scientific-advice briefing book after a pediatric ethicist objecting to the proposed design: if scientific-advice briefing book supports it, clinical-development physician executes Proceed under protocol in a company with a CMC site change mid-review and logs the owner. If scientific-advice briefing book instead fits Pause the pathway, take that path. Where scientific-advice briefing book after a pediatric ethicist objecting to the proposed design is silent, clinical-development physician must state the unresolved clinical or safety evidence requirement explicitly.